The Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib (Merck) may offer a new treatment option for patients with B-cell blood cancers such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. This news comes from a recent study in the journal Cancer Discovery (2023 Nov 6. doi:10.1158/2159-8290.CD-23-0670).
The researchers tested the new drug on 47 patients who have had at least two prior therapies for their
NOVEMBER 21, 2023